文献速递血栓与止血

Giroctocogene fitelparvovec基因治疗重型血友病A:1/2期Alta研究104周分析

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
PubMed 文献 · Blood · 2024-01-01

这项正在进行的1/2期剂量递增Alta研究纳入11例重型血友病A男性受试者,单次静脉输注giroctocogene fitelparvovec。最高剂量组(3×10^13 vg/kg,n=5)第52周平均循环FVIII活性为42.6%(范围7.8%-122.3%),第104周为25.4%(范围0.9%-71.6%)。转氨酶升高为最常见治疗相关不良事件,经糖皮质激素治疗后缓解;未检测到肝脏肿块、血栓事件或确认的抑制物。

要点

  • 最高剂量组第52周平均FVIII活性42.6%,第104周降至25.4%(显色法)。
  • 转氨酶升高为最常见治疗相关不良事件,经糖皮质激素治疗后缓解。
  • 1例受试者发生2起治疗相关严重不良事件(低血压和发热),输注后24小时内缓解。

核心结论

  • 这些104周中期数据提示,在适当的临床管理下giroctocogene fitelparvovec总体耐受性良好,并有可能提供有临床意义的FVIII活性水平,最高剂量队列出血事件发生率低。

研究设计与样本

  • 正在进行的1/2期剂量递增Alta研究(NCT03061201),4个序贯队列的重型血友病A男性受试者接受单次静脉输注giroctocogene fitelparvovec,主要终点为安全性和循环FVIII活性变化,报告所有受试者治疗后最长214周的期中结果,共11例受试者接受给药。

主要发现

  • 丙氨酸转氨酶和天冬氨酸转氨酶升高是最常见的治疗相关不良事件,经糖皮质激素给药后缓解。
  • 1例受试者发生2起治疗相关严重不良事件(低血压和发热),发生于输注后6小时内,输注后24小时内缓解。
  • 最高剂量组(3×10^13 vg/kg;n=5)基于显色法测定的第52周平均循环FVIII活性为42.6%(范围7.8%-122.3%),第104周为25.4%(范围0.9%-71.6%)。
  • 任何受试者均未检测到肝脏肿块、血栓事件或确认的抑制物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with hemophilia A require exogenous factor VIII (FVIII) or nonfactor hemostatic agents to prevent spontaneous bleeding events. Adeno-associated virus (AAV) vector-based gene therapy is under clinical investigation to enable endogenous FVIII production. Giroctocogene fitelparvovec is a recombinant AAV serotype 6 vector containing the coding sequence for the B-domain-deleted human F8 gene. In the ongoing phase 1/2, dose-ranging Alta study, 4 sequential cohorts of male participants with severe hemophilia A received a single IV dose of giroctocogene fitelparvovec. The primary end points are safety and changes in circulating FVIII activity. Interim results up to 214 weeks after treatment for all participants are presented. Eleven participants were dosed. Increases in alanine and aspartate aminotransferases were the most common treatment-related adverse events (AEs), which resolved with corticosteroid administration. Two treatment-related serious AEs (hypotension and pyrexia) were reported in 1 participant within 6 hours of infusion and resolved within 24 hours after infusion. At the highest dose level (3 × 1013 vg/kg; n = 5), the mean circulating FVIII activity level at week 52 was 42.6% (range, 7.8%-122.3%), and at week 104 it was 25.4% (range, 0.9%-71.6%) based on a chromogenic assay. No liver masses, thrombotic events, or confirmed inhibitors were detected in any participant. These interim 104-week data suggest that giroctocogene fitelparvovec is generally well tolerated with appropriate clinical management and has the potential to provide clinically meaningful FVIII activity levels, as indicated by the low rate of bleeding events in the highest dose cohort. This trial was registered at www.clinicaltrials.gov as #NCT03061201.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Leavitt AD, Konkle BA, Stine KC, et al. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study. Blood. 2024. PMID: 37871576. doi:10.1182/blood.2022018971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。